Developing a new therapy capable of completely regenerating the heart after a myocardial infarction, forming new tissue and new blood vessels to restore the heart muscle to full function: this is the goal of the RESCUE international research project - Bridging the gap between cardiac regeneration and revascularization coordinated by the University of Trieste, which involves experts in cardiac regeneration and angiogenesis from Italy, Spain, the Netherlands, Slovakia and Turkey.

‘For many years, progress in the fields of cardiac regeneration and angiogenesis have proceeded in the same direction, without talking to each other. However, repairing a heart damaged by an infarction requires the formation of both new heart muscle and new blood vessels. With the RESCUE project, we aim to bridge this gap between cardiac regeneration and revascularisation: we want, in fact, to develop a new biological drug containing two active ingredients - and in particular two RNA molecules - that can regenerate the heart and simultaneously promote the vascularisation of the regenerated tissue,' explains project coordinator Serena Zacchigna, professor of molecular biology at the department of medical, surgical and health sciences at the University of Trieste and head of the cardiovascular biology laboratory at ICGEB (International Centre for Genetic Engineering and Biotechnology).

The researchers have already identified a number of candidate molecules, which have been shown to promote the proliferation of heart muscle cells on the one hand and the formation of new blood vessels, both small capillaries and larger arteries, on the other. Over the next three years, researchers will experiment with different combinations until they identify the most effective one. This will be the first time that two biological molecules, capable of stimulating these two fundamental processes for the repair of an infarcted heart, are combined in a single drug, to demonstrate synergy of action. 

The University of Trieste – the only Italian university leading one of the seventeen projects selected by the CARDINNOV call for proposals – will coordinate the study in collaboration with the Monzino Cardiological Centre Research Hospital, in particular with the research group of Prof. Giulio Pompilio, scientific director and alternate Italian delegate to the Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA). 

'Myocardial infarction continues to be a major cause of death,' explains Prof. Giulio Pompilio, scientific director of the Monzino Cardiological Centre Research Hospital. 'Research has recently produced new RNA drugs that act on the risk factors of infarction, but there are still no therapies that stimulate heart repair. In the coming years, we expect more and more RNA drugs to be introduced into the clinic for the treatment of heart disease,' the professor concludes.

The National Centre for Cardiovascular Research (CNIC) in Madrid, the University of Utrecht, the Lokman Hekim University in Ankara, the Slovak Academy of Sciences, and the PLN Foundation patient association, the latter of which is responsible for educating and raising awareness among patients and caregivers about the new RNA therapies, are collaborating on the project. 

With funding of EUR 1.5 million - of which more than 600,000 are earmarked for Italy, through the Ministry of University and Research and the Ministry of Health - the project is promoted by the EU ERA4Health partnership, which supports collaboration between various European and international research bodies in priority areas in the health sector, fostering the development of therapeutic innovations..